DDrare: Database of Drug Development for Rare Diseases

Searched query = "Inclusion body myositis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = ABC008; ARIMOCLOMOL; Alemtuzumab; Alemtuzumab (Campath); Anakinra; Arimoclomol; Arimoclomol citrate; BOTULINUM TOXIN TYPE A; BRX-345; BYM338; BYM338 (Bimagrumab); BYM338/bimagrumab; Bimagrumab; Botulinum toxin type A; Care as usual; Etanercept; FLEBOGAMMA 5%; Gamma Globulin; Immunoglobulins, normal human, for intravascular adm.; Natalizumab; Null; Other: Blood-flow restricted training; Phenylbutyrate; Phenylbutyrate Oral Tablet; Pioglitazone; RAAV1.CMV.huFollistatin344; REGN2477+REGN1033; Rapamycin; SIVASTIN; Simvastatin; Sivastin; Xeomin

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00079768 (ClinicalTrials.gov)	March 2004	12/3/2004	Alemtuzumab to Treat Sporadic Inclusion Body Myositis	Effects of a T Cell-Depleting Monoclonal Antibody, Alemtuzumab, in Patients With Inclusion Body Myositis: A Pilot Clinicopathological Study	Myositis, Inclusion Body	Drug: Alemtuzumab (Campath)	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Completed	25 Years	80 Years	Both	20	Phase 2	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT00079768
(ClinicalTrials.gov)

March 2004

12/3/2004

Alemtuzumab to Treat Sporadic Inclusion Body Myositis

Effects of a T Cell-Depleting Monoclonal Antibody, Alemtuzumab, in Patients With Inclusion Body Myositis: A Pilot Clinicopathological Study

Myositis, Inclusion Body

Drug: Alemtuzumab (Campath)

National Institute of Neurological Disorders and Stroke (NINDS)

NULL

Completed

25 Years

80 Years

Both

Phase 2

United States